|
MechanismTGF-β1 inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhaseEarly Phase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
|
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Humanized CAR19T2 T Cell in Children With Refractory/Relapsed B-cell Leukemia/Lymphoma
This study aims to evaluate the safety and efficacy of humanized Anti-CD19 Chimeric Antigen Receptor-T cell (CAR19T2 T cell) in children with refractory/relapsed B-cell acute lymphoblastic leukemia/lymphoma.
100 Clinical Results associated with Guangdong Zhaotai Cell Biotechnology Co., Ltd
0 Patents (Medical) associated with Guangdong Zhaotai Cell Biotechnology Co., Ltd
100 Deals associated with Guangdong Zhaotai Cell Biotechnology Co., Ltd
100 Translational Medicine associated with Guangdong Zhaotai Cell Biotechnology Co., Ltd